2 results
Approved WMOPending
The central hypothesis of this project is that atorvastatin (added on standard antihypertensive treatment ARB) causes a substantial decrease in MSNA in hypertensive patients with CKD.
Approved WMOPending
Our primary objective is to investigate the effects of endotoxin-induced systemic inflammation and subsequent development of endotoxin tolerance on the inflammatory response following Fluenz® administration in vivo. To evaluate whether these effects…